David Wheeler
Pulmonary Disease · Philadelphia, PANPI 1386906808
Payments from drug & device makers
$7,725,353in general payments, 2019–2025
Across 618 payments — averaging $12,501 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$6.3M
- Pfizer$1.4M
- GSK$80K
- Teva Pharmaceuticals USA, Inc.$19K
What the payments were for
- Consulting fees$2,00097%
- Travel & lodging$291%
- Food & beverage$342%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 465 | $6,267,409 |
| Pfizer | 98 | $1,359,077 |
| GSK | 40 | $80,174 |
| Teva Pharmaceuticals USA, Inc. | 15 | $18,692 |
How this compares
$7,725,353 in reported general payments places this provider in the 95th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Philadelphia
- Gerard CrinerPhiladelphia$18.2M
- Steven AlbeldaPhiladelphia$5.5M
- Steven KelsenPhiladelphia$847K
- Parth RaliPhiladelphia$814K
- Kartik ShenoyPhiladelphia$701K
- Christopher ManleyPhiladelphia$580K
- Michaela AndersonPhiladelphia$515K
- Michael BaramPhiladelphia$501K
- Ross SummerPhiladelphia$483K
- Julie BartaPhiladelphia$409K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.